<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734123</url>
  </required_header>
  <id_info>
    <org_study_id>UDETMA_08</org_study_id>
    <secondary_id>UDETMA_2008_001</secondary_id>
    <nct_id>NCT00734123</nct_id>
  </id_info>
  <brief_title>Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.</brief_title>
  <acronym>PRIMARIA</acronym>
  <official_title>Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Arnau de Vilanova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of cardiovascular diseases is still high and further efforts should be done in
      primary prevention. The main objective is to quantify the burden of subclinical
      atherosclerosis using non-invasive techniques,and to study the impact of this assessment and
      consequent treatment in the progression of atherosclerosis and in the incidence of
      cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will perform non-invasive techniques (carotid Intima-Media Thickness, CAC score and
      ankle-brachial index) to individuals at intermediate cardiovascular risk.With these results,
      we will classify participants in: no atherosclerosis, mild, moderate and severe
      atherosclerosis, and therapeutic targets will be set according to pre-defined algorithms. The
      end-point will be the course of atherosclerosis measured by cIMT/CAC score (2 years) and the
      incidence of CVD at 5 years of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid Intima-Media Thickness progression/regression</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardio and cerebrovascular eventS</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2948</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to control group (2) will be followed according to the clinical standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin or Atorvastatin</intervention_name>
    <description>Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Simvastatin 10-40.</other_name>
    <other_name>Atorvastatin 20-40.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly</description>
    <arm_group_label>1</arm_group_label>
    <other_name>ACE inhibitors.</other_name>
    <other_name>ACE + diuretic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin or clopidogrel</intervention_name>
    <description>Aspirin 100 mg or clopidogrel 75 mg/ per day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Antiplatelets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimonabant</intervention_name>
    <description>In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.
Drugs will be prescribed as the standard clinical care</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Rimonabant is allowed.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        One or more of the following:

          -  Familiar History of early-onset cardiovascular disease (male &lt; 55 or female &lt; 65).

          -  Type 2 Diabetes mellitus or type 1 with microalbuminuria.

          -  Essential High Blood Pressure.

          -  Chronic Kidney Disease.

          -  Primary hyperlipidemia.

        The presence of two or more of the following:

          -  Current smoker.

          -  Physical inactivity.

          -  High blood pressure (recently diagnosed).

          -  Abdominal perimeter: &gt; 102 cm. males; &gt; 88 cm. females.

          -  Total cholesterol &gt; 240 mg/dL.

          -  HDL cholesterol ≤ 40 mg/dL males, ≤ 50 mg/dL females.

        Exclusion Criteria:

          -  Age &lt; 40 or &gt; 74 years old.

          -  Previous Cardiovascular Event.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elvira Fernandez, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Arnau de Vilanova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blai Coll, MD,PhD</last_name>
    <phone>+34 619633249</phone>
    <email>bcoll@arnau.scs.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <state>Catalunya</state>
        <zip>25260</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blai Coll, MD,PhD</last_name>
      <phone>+34 619633249</phone>
      <email>bcoll@arnau.scs.es</email>
    </contact>
    <investigator>
      <last_name>Blai Coll, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Merce Borras, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>August 13, 2008</last_update_submitted>
  <last_update_submitted_qc>August 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2008</last_update_posted>
  <responsible_party>
    <name_title>Elvira Fernandez</name_title>
    <organization>Hospital Arnau de Vilanova</organization>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Cardiovascular Prevention</keyword>
  <keyword>Carotid Intima-Media Thickness</keyword>
  <keyword>Ankle-Brachial Index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

